Powered by: Motilal Oswal
2026-08-24 03:20:52 pm | Source: Motilal Oswal Financial Services Ltd
Buy Tube Investments of India Ltd For Target Rs.3,379 by Motilal Oswal Financial Services Ltd
Buy Tube Investments of India Ltd For Target Rs.3,379 by Motilal Oswal Financial Services Ltd

In-line earnings despite margin miss TI Medical and CDMO to ramp up in FY27

* Tube Investments’ (TIINDIA) 1QFY27 adj. PAT at INR1.6b came in line with our est. despite a 70bp miss on EBITDA margin. MFD was the worstperforming segment, with segmental margins contracting 320bp YoY.

* Despite near-term margin headwinds, TIINDIA offers diversified revenue streams, with steady growth in the core business (~7% S/A PAT CAGR over FY26-28E) and CG Power, as well as the optionality of new businesses incubated under the TI-2 strategy. We reiterate our BUY rating with a TP of ~INR3,379 (premised on FY28E SoTP; our valuation is based on a 15x PER for the standalone business, valuing the listed subsidiaries at a 35% HoldCo discount).

Earnings in line

* TII’s standalone revenue grew 18% YoY to INR23.6b (6% above our est.). EBITDA margin contracted 190bp YoY to 10.4% (vs our est. of 11.1%).

* Segmental performance:

* Mobility business revenue grew 26% YoY to INR2.5b, while EBIT margin was largely flat YoY at 3.6%.

* Engineering business revenue grew 21% YoY to INR15.6b, while EBIT margin contracted 200bp YoY to 9.8%.

* MFB revenue grew 12% YoY to INR4.1b, while EBIT margin contracted 320bp YoY to 6.8%.

* Other business revenue grew 8% YoY to INR2.56b, while EBIT margin expanded 90bp YoY to 8.1%.

* As a result, EBITDA was largely flat YoY at INR2.5b (in line). ? Adj. PAT declined 6% YoY to INR1.6b (in line).

Highlights from the management commentary

* TII’s core business remains fundamentally strong, with the Engineering business having delivered 17% volume growth and exports growing in double digits, while MFP revenue growth improved to 11.5% during the quarter. Further, with the 2-3 quarter lagged recovery of steel inflation, management expects margins to recover and improve, despite near-term margins remaining under pressure due to input cost inflation.

* TII is building multiple growth engines beyond their core business. TI Medical continues to target ~20% growth, while the 3xper CDMO platform is progressing toward commercial scale-up. Investments in additive manufacturing and optoelectronics further expand the company's addressable markets.

* 1Q marked record revenue of ~INR2.4b for TI Clean Mobility, with strong traction across HCVs, SCVs, and three-wheelers. Management indicated that peak quarterly losses are likely behind the business.

Valuation and view

* Despite near-term margin headwinds, TIINDIA offers diversified revenue streams, with steady growth in the core business (~7% S/A PAT CAGR over FY26- 28E) and CG Power, as well as the optionality of new businesses incubated under the TI-2 strategy. We reiterate our BUY rating with a TP of ~INR3,379 (premised on FY28E SoTP; our valuation is based on a 15x PER for the standalone business, valuing the listed subsidiaries at a 35% HoldCo discount)

 

For More Research Reports : Click Here 

For More Motilal Oswal Securities Ltd Disclaimer
http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html
SEBI Registration number is INH000000412

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here